Illumina's sequencing business shows signs of recovery, raising questions about stock valuation.
Illumina Inc's sequencing business is reportedly recovering, yet concerns are emerging about whether the current stock price accurately reflects this recovery. The company's stock closed at US$276.67, down 0.54% on the day, but it has seen a significant increase of 34.01% over the past month, with a year-to-date rise of 105.93%.
Advertisement
Illumina Inc
ILMN.US
ILMN.US
Illumina Inc
WealthAwesomeMarket cap
$41.78B
P/E
51.6x
52W high
$309.35
52W low
$90.10
1W change
-5.80%
Beta
1.42
Analyst Price Targets
Based on 21 analysts covering ILMN · as of Oct 13, 2026
Wall Street analysts forecast ILMN stock price to fall 15.6% over the next 12 months.
Consensus
Buy3.57 / 5.00
Avg. Target
C$233.55
-15.6% Upside
Previously C$229.10 on Oct 12, 2026
Current Price
C$276.67
Last close
Analyst Breakdown (21 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ILMN's historical volatility
30-Day Vol
57.1%
Annualized
90-Day Vol
48.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$330.76
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$293.64 | C$241.13 – C$357.59 |
| 60 trading days | C$311.65 | C$235.86 – C$411.79 |
| 90 trading days | C$330.76 | C$235.13 – C$465.29 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should weigh the implications of the business recovery against the current stock valuation.
Illumina's Stock Closes at US$276.67 Amid Recovery News
The stock's performance reflects a 34.01% increase over the past month, despite a recent decline.
Bull case
Illumina's recovery in its sequencing business could pave the way for future growth and profitability.
Bear case
The stock might be overvalued based on analyst targets and current market conditions.
Illumina’s Sequencing Business Shows Signs of Recovery
Advertisement
Recent reports indicate that Illumina's sequencing business is on the mend. This news comes as the stock closes at US$276.67, reflecting a slight decline of 0.54% for the day. However, the stock has rebounded significantly, with a 34.01% increase over the past month and an impressive 105.93% rise year-to-date. Still, it remains uncertain whether this recovery aligns with the stock's current valuation.
Stock Performance and Market Metrics
Illumina's stock performance has been quite volatile, with the latest trading volume at 1,642,657 shares, which is only 0.36 times the 20-day average volume of 4,547,642 shares. The stock is currently trading well above its 50-day moving average of US$228.35, by approximately 21.2%, and its 200-day moving average of US$166.97, by about 65.7%. The stock has a P/E ratio of 51.62, suggesting it may be valued at a premium compared to its earnings.
What to Watch Next for Illumina
Looking ahead, investors should monitor Illumina's upcoming earnings reports and any further developments in its sequencing business to evaluate the sustainability of its recovery. The stock's current position in the 52-week range is noteworthy, trading between US$90.10 and US$309.35, which means it is currently at about 85% of its range. Additionally, the average analyst target for the stock is US$233.55, indicating a potential downside of 15.6% from the current price, raising concerns about whether the stock is overvalued.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
